▶ 調査レポート

世界の肺動脈性肺高血圧症(PAH)市場2021年ー2028年:パイプライン別(初期段階薬剤候補[第I相、第II相]、後期段階薬剤候補[第III相、登録段階])、薬剤分類別

• 英文タイトル:Pulmonary Arterial Hypertension (PAH) Market (Pipeline Analysis: Early-stage Drug Candidates [Phase I & Phase II] and Late-stage Drug Candidates [Phase III & Registration Phase]; and Drug Class: Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists [ERAs], Phosphodiesterase-5 [PDE-5] Inhibitors, and Soluble Guanylate Cyclase [sGC] Stimulators) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Transparency Market Researchが調査・発行した産業分析レポートです。世界の肺動脈性肺高血圧症(PAH)市場2021年ー2028年:パイプライン別(初期段階薬剤候補[第I相、第II相]、後期段階薬剤候補[第III相、登録段階])、薬剤分類別 / Pulmonary Arterial Hypertension (PAH) Market (Pipeline Analysis: Early-stage Drug Candidates [Phase I & Phase II] and Late-stage Drug Candidates [Phase III & Registration Phase]; and Drug Class: Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists [ERAs], Phosphodiesterase-5 [PDE-5] Inhibitors, and Soluble Guanylate Cyclase [sGC] Stimulators) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028 / MRC2205A023資料のイメージです。• レポートコード:MRC2205A023
• 出版社/出版日:Transparency Market Research / 2022年3月11日
• レポート形態:英文、PDF、129ページ
• 納品方法:Eメール
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥770,735 (USD5,795)▷ お問い合わせ
  Multi User¥1,169,735 (USD8,795)▷ お問い合わせ
  Corporate License¥1,568,735 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Transparency Market Research社の本調査レポートは、世界の肺動脈性肺高血圧症(PAH)市場について調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、パイプライン別(初期段階薬剤候補[第I相、第II相]、後期段階薬剤候補[第III相、登録段階])分析、薬剤分類別分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)分析、競争状況などの項目を掲載しています。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場概要
・キーインサイト
・世界の肺動脈性肺高血圧症(PAH)市場規模:パイプライン別(初期段階薬剤候補[第I相、第II相]、後期段階薬剤候補[第III相、登録段階])
・世界の肺動脈性肺高血圧症(PAH)市場規模:薬剤分類別
・世界の肺動脈性肺高血圧症(PAH)市場規模:地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)
・競争状況

Pulmonary Arterial Hypertension (PAH) Market – Scope of Report

TMR’s report on the global pulmonary arterial hypertension market studies the past as well as current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2028. The report provides revenue of the global pulmonary arterial hypertension market for the period 2017–2028, considering 2020 as the base year and 2021 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global pulmonary arterial hypertension market during the forecast period.

The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global pulmonary arterial hypertension market.

Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global pulmonary arterial hypertension market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global pulmonary arterial hypertension market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global pulmonary arterial hypertension market.

The report delves into the competitive landscape of the global pulmonary arterial hypertension market. Key players operating in the global pulmonary arterial hypertension market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global pulmonary arterial hypertension market that have been profiled in this report.

Key Questions Answered in Pulmonary Arterial Hypertension (PAH) Market Report
What is the scope of growth of product companies in the global pulmonary arterial hypertension market?
What will be the Y-o-Y growth of the global pulmonary arterial hypertension market between 2017 and 2028?
What is the influence of changing trends in technologies on the global pulmonary arterial hypertension market?
Will North America continue to be the most profitable market for pulmonary arterial hypertension product providers?
Which factors are anticipated to hamper the growth of the global pulmonary arterial hypertension market during the forecast period?
Which are the leading companies in the global pulmonary arterial hypertension market?

Research Methodology
TMR has utilized a unique research methodology to conduct a comprehensive research on the growth of the global pulmonary arterial hypertension market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary methods referred to by analysts during the production of the global pulmonary arterial hypertension market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the pulmonary arterial hypertension market as primary methods.

These primary and secondary methods have provided exclusive information during interviews, which serves as a validation from the pulmonary arterial hypertension market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global pulmonary arterial hypertension market with accuracy. The study also uses the top-down approach to assess the revenue for each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global pulmonary arterial hypertension market more reliably and accurately.

レポート目次

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Pulmonary Arterial Hypertension (PAH) Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast, 2017–2028
5. Key Insights
5.1. Healthcare Industry Overview
5.2. Top 3 players operating in the market space
5.3. Technological Advancements
5.4. Key Mergers & Acquisitions
5.5. Disease Prevalence & Incidence Rate globally with key countries
5.6. COVID-19 Pandemics Impact on Industry (value chain and short / mid / long term impact)
6. Global Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2017–2028
6.3.1. Prostacyclin & Prostacyclin Analogs
6.3.2. Endothelin Receptor Antagonists (ERAs)
6.3.3. Phosphodiesterase-5 (PDE-5) Inhibitors
6.3.4. Soluble Guanylate Cyclase (sGC) Stimulators
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast, by Pipeline Analysis
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Pipeline Analysis, 2017–2028
7.3.1. Early-stage Drug Candidates (Phase I & Phase II)
7.3.2. Late-stage Drug Candidates (Phase III & Registration Phase)
7.4. Market Attractiveness Analysis, by Pipeline Analysis
8. Global Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Country/Region
9. North America Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Drug Class, 2017–2028
9.2.1. Prostacyclin & Prostacyclin Analogs
9.2.2. Endothelin Receptor Antagonists (ERAs)
9.2.3. Phosphodiesterase-5 (PDE-5) Inhibitors
9.2.4. Soluble Guanylate Cyclase (sGC) Stimulators
9.3. Market Value Forecast, by Pipeline Analysis, 2017–2028
9.3.1. Early-stage Drug Candidates (Phase I & Phase II)
9.3.2. Late-stage Drug Candidates (Phase III & Registration Phase)
9.4. Market Value Forecast, by Country, 2017–2028
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By Pipeline Analysis
9.5.3. By Country
10. Europe Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017–2028
10.2.1. Prostacyclin & Prostacyclin Analogs
10.2.2. Endothelin Receptor Antagonists (ERAs)
10.2.3. Phosphodiesterase-5 (PDE-5) Inhibitors
10.2.4. Soluble Guanylate Cyclase (sGC) Stimulators
10.3. Market Value Forecast, by Pipeline Analysis, 2017–2028
10.3.1. Early-stage Drug Candidates (Phase I & Phase II)
10.3.2. Late-stage Drug Candidates (Phase III & Registration Phase)
10.4. Market Value Forecast, by Country/Sub-region, 2017–2028
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By Pipeline Analysis
10.5.3. By Country/Sub-region
11. Asia Pacific Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017–2028
11.2.1. Prostacyclin & Prostacyclin Analogs
11.2.2. Endothelin Receptor Antagonists (ERAs)
11.2.3. Phosphodiesterase-5 (PDE-5) Inhibitors
11.2.4. Soluble Guanylate Cyclase (sGC) Stimulators
11.3. Market Value Forecast, by Pipeline Analysis, 2017–2028
11.3.1. Early-stage Drug Candidates (Phase I & Phase II)
11.3.2. Late-stage Drug Candidates (Phase III & Registration Phase)
11.4. Market Value Forecast, by Country/Sub-region, 2017–2028
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By Pipeline Analysis
11.5.3. By Country/Sub-region
12. Latin America Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017–2028
12.2.1. Prostacyclin & Prostacyclin Analogs
12.2.2. Endothelin Receptor Antagonists (ERAs)
12.2.3. Phosphodiesterase-5 (PDE-5) Inhibitors
12.2.4. Soluble Guanylate Cyclase (sGC) Stimulators
12.3. Market Value Forecast, by Pipeline Analysis, 2017–2028
12.3.1. Early-stage Drug Candidates (Phase I & Phase II)
12.3.2. Late-stage Drug Candidates (Phase III & Registration Phase)
12.4. Market Value Forecast, by Country/Sub-region, 2017–2028
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Pipeline Analysis
12.5.3. By Country/Sub-region
13. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017–2028
13.2.1. Prostacyclin & Prostacyclin Analogs
13.2.2. Endothelin Receptor Antagonists (ERAs)
13.2.3. Phosphodiesterase-5 (PDE-5) Inhibitors
13.2.4. Soluble Guanylate Cyclase (sGC) Stimulators
13.3. Market Value Forecast, by Pipeline Analysis, 2017–2028
13.3.1. Early-stage Drug Candidates (Phase I & Phase II)
13.3.2. Late-stage Drug Candidates (Phase III & Registration Phase)
13.4. Market Value Forecast, by Country/Sub-region, 2017–2028
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By Pipeline Analysis
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2020
14.3. Company Profiles
14.3.1. Actelion Pharmaceuticals Ltd.
14.3.1.1. Company Overview (HQ, Business Segments, Employee)
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Strategic Overview
14.3.2. Gilead Sciences, Inc.
14.3.2.1. Company Overview (HQ, Business Segments, Employee)
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Strategic Overview
14.3.3. Pfizer, Inc.
14.3.3.1. Company Overview (HQ, Business Segments, Employee)
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Strategic Overview
14.3.4. GlaxoSmithKline plc
14.3.4.1. Company Overview (HQ, Business Segments, Employee)
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Strategic Overview
14.3.5. United Therapeutics Corp
14.3.5.1. Company Overview (HQ, Business Segments, Employee)
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Strategic Overview
14.3.6. Novartis International AG
14.3.6.1. Company Overview (HQ, Business Segments, Employee)
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Strategic Overview
14.3.7. Bayer HealthCare
14.3.7.1. Company Overview (HQ, Business Segments, Employee)
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Strategic Overview
14.3.8. Other prominent players
14.3.8.1. Company Overview (HQ, Business Segments, Employee)
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Strategic Overview